Melatonin interaction with BZ-GabaA receptors: Implications for sleep induction

Sleep and Sleep Disorders: A Neuropsychopharmacological Approach

Volumn , Issue , 2006, Pages 95-99

  Niles, Lennard P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920041213     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-27682-3_8     Document Type: Chapter

References (62)

1. Dubocovich ML, Cardinali DP, Guardiola-Lemaitre B et al. Melatonin receptors. In: Girdlestone D, ed. The lUPHAR Compendium of Receptor Characterization and Classification. London: lUPHAR Media, 1998:187-193.
2. Vanecek J. Cellular mechanisms of melatonin aaion. Physiol Rev 1998; 78:687-721.
3. Niles LP. G protein-coupled melatonin receptors. In: Mishra RK, Baker GB, Boulton AA, eds. G Protein Methods and Protocols: Role of G Proteins in Psychiatric and Neurological Disorders. Neuromethods. New Jersey: Humana Press, 1997:31:223-281.
4. McArthur AJ, Hunt AE, Gillette MU. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology 1997; 138:627-634.
5. Anton-Tay F, Ramirez G, Martinez I et al. In Vitro Stimulation of protein kinase C by melatonin. Neurochemical Res 1998; 23 601:606.
6. Brydon L, Petit L, Delagrange P et al. Funaional expression of MT2 (Mellb) melatonin receptors in human PAZ6 adipocytes. Endocrinology 2001; 142:4264-4271.
7. Roy D, Belsham DD. Melatonin receptor activation regulates GnRH gene expression and secretion in GTl-7 GnRH neurons. J Biol Chem 2002; 277:251-258.
8. Armstrong KJ, Niles LP. Induaion of GDNF mRNA expression by melatonin in rat C6 glioma cells. NeuroReport 2002; 13:473-475.
9. Golombek DA, Martinin M, Cardinali DP. Melatonin as an anxiolytic in rats: Time dependence and interaction with the central GABAergic system. Eur J Pharmacol 1993; 237:231-236.
10. Tenn CC, Niles LP. Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: Involvement of a GABAergic mechanism. J Pharmacol Exp Ther 1995; 274:84-89.
11. Sieghart W. Structure and pharmacology of y aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47:181-234.
12. Costa E. From GABAA receptor diversity emerges a unified vision of GABAergic inhibition. Annu Rev Pharmacol Toxicol 1998; 38:321-350.
13. Tenn CC, Niles LP. Modulation of dopaminergic activity in the striatum by benzodiazepines and melatonin. Pharmacol Rev Comm 2002; 12:171-178.
14. Parola AL, Yamamura HI, Laird HE. Peripheral-type benzodiazepine receptors. Life Sci 1993; 52:1329-1342.
15. 3H] flunitrazepam binding sites. J Neurochem 1987; 49:890-899.
16. Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharmaceut Design 2002; 8:5-21.
17. Sigel E, Buhr A. The benzodiazepine binding site of GABAA receptors. Trends Pharmacol Sci 1997; 18:425-429.
18. Sur C, WafFord KA, Reynolds DS et al. Loss of die major GABA(A) receptor subtype in the brain is not lethal in mice. J Neurosci 2001; 21:3409-3418.
19. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002; 300:2-8.
20. Pritchett DB, Seeburg PH. γ-Aminobutyric acidA receptor a5 subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 1990; 54:1802-1804.
21. A receptor subunit mRNAs in the rat brain. I Telencephalon, diencephalon, mesencephalon. J Neurosci 1992; 12:1040-1062.
22. Tobler I, Kopp C, Deboer T et al. Diazepam-induced changes in sleep: Role of the a l GABAA receptor subtype. Proc Natl Acad Sci 2001; 98:6464-6469.
23. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002; 40:475-486.
24. McEnery MW, Snowman AM, Trifiletti RR et al. Isolation of the mitochondrial benzodiazepine receptor: Association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Nad Acad Sci USA 1992; 89:3170-3174.
25. Papadopoulos V. Structure and function of the peripheral-type benzodiazepine receptor in steroidogenic cells. Proc Soc Exp Biol Med 1998; 217:130-142.
26. Oke BO, Suarez-Quian CA, Riond J et al. Cell surface localization of the peripheral-type benzodiazepine receptor in adrenal cortex. Mol Cell Endocrinol 1992; 87:R1-R6.
27. Woods MJ, Zisterer DM, Williams DC. Two cellular and subcellular locations for the peripheral-type benzodiazepine receptor in rat liver. Biochem Pharmacol 1996; 51:1283-1292.
28. Tenn CC, Neu JM, Niles LP PK 11195 blockade of benzodiazepine-induced inhibition of forskolin-stimidated adenylate cyclase activity in the striatum. Brit J Pharmacol 1996; 119:223-228.
29. Tenn CC, Niles LP. Sensitization of G protein coupled benzodiazepine receptors in the striatum of 6-hydroxydopamine lesioned rats. J Neurochem 1997; 69:1920-1926.
30. Lambert JJ, Belelli D, Hill-Venning C et al. Neurosteroids and GABAA receptor flinaion. Trends Pharmacol Sci 1995; 16:295-303.
31. Brot MD, Akwa Y, Purdy RH et al. The anxiolytic-like effects of the neurosteroid allopregnanolone: Intractions with GABAA receptors. Eur J Pharmacol 1997; 325:1-7.
32. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001; 145:669-679.
33. Wan Q, Man HY, Liu F et al. Differential modulation of GABAA receptor function by Mel la and Mellbreceptors. Nat Neurosci 1999; 2:401-403.
34. Niles LP. Melatonin interaction with the benzodiazepine-GABA receptor complex in the CNS. In: Schwarcz R, Young SN, Brown RR, eds. Kynurenine and Serotonin Pathways: Progress in Tryptophan Research. Advances in Experimental Medicine and Biology. New York: Plenum Press, 1991:294:267-277.
35. 35S]butylcyclophosphorothionate binding in rat brain by melatonin. Brain Res Bull 1990; 24:635-638.
36. Joseph-Liauzun E, Farges R, Delmas P et al. The Mr 18, 000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier. J Biol Chem 1997; 272:28102-6.
37. Mellon SH, Griffin LD. Neurosteroids: Biochemistry and clinical significance. Trends Endocrinol Metab 2002; 13:35-43.
38. Areceptor by cAMP-dependent protein kinase and by protein kinase C: Analysis of the substrate domain. Neurochem Res 1993; 18:95-10.
39. Poisbeau P, Cheney MC, Browning M.D et al. Modulation of synaptic GABAA receptor function by PKA and PKC in adult hippocampal neurons. J Neurosci 1999; 19:674-683.
40. Wan Q, Man HY, Braunton J et al. Modulation of GABAA receptor function by tyrosine phosphorylation of beta subunits. J Neurosci 1997; 17:5062-5069.
41. Itzhak Y, Baker L, Norenberg MD. Characterization of the peripheral-type benzodiazepine receptors in cultured astrocytes: Evidence for multiplicity. Glia 1993; 9:211-8.
42. Pierrefiche G, Zerbib R, Laborit H. Anxiolytic activity of melatonin in mice: Involvement of benzodiazepine receptors. Res Comm Chem Pathol Pharmacol 1993; 82:131-142.
43. Green AR, Nutt DJ, Cowen PJ. Using Ro 15-1788 to investigate the benzodiazepine receptor in vivo: Studies on the anticonvulsant and sedative effect of melatonin and the convulsant effect of the benzodiazepine Ro 05-3663. Psychopharmacol 1982; 78:293-295.
44. Golombek DA, Duque DF, De Brito Sanchez MG et al. Time-dependent anticonvulsant activity of melatonin in hamsters. Eur J Pharmacol 1992; 210:253-258.
45. A receptor mediates the hypnotic activity of melatonin in rats. Pharmacol Biochem Behav 2003; 74:573-578.
46. Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp. Ther 1983; 227:587-591.
47. Golombek DA, Escolar E, Cardinali DP. Melatonin-induced depression of locomotor activity in hamsters: Time-dependency and inhibition by the central-type benzodiazepine antagonist Ro 15-1788. Physiol Behav 1991; 49:1091-1097.
48. DoUins AB, Zhdanova IV, Wurtman RJ et al. Effea of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Nad Acad Sci USA 1994; 91:1824-1828.
49. Hajak G, Rodenbeck A, Staedt J et al. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res 1995; 19:116-122.
50. Waldhauser F, Weiszenbacher G, Tatzer E et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988; 66:648-652.
51. Van Coevorden A, Mockel J, Laurent E et al. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991; 260:E651-61.
52. Garfinkel D, Laudon M, Nof D et al. Improvement of sleep quality in elderly people by controUed-release melatonin. Lancet 1995; 346:541-544.
53. Zhdanova IV, Wang SY, Leclair OU et al. Melatonin promotes sleep-like state in zebrafish. Brain Res 2001; 903:263-268.
54. Gottesmann C. GABA mechanisms and sleep. Neurosci 2002; 111:231-239.
55. Kushikata T, Kubota T, Fang J et al. Glial cell line-derived neurotrophic factor promotes sleep in rats and rabbits. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1001-1006.
56. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: A sleep-promoting hormone. Sleep 1997; 20:899-907.
57. MacFarlane JG, Cleghorn JM, Brown CM et al. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: A preliminary study. Biol Psychiatry 1991; 30:371-376.
58. Stone BM, Turner C, Mills SL et al. Hypnotic activity of melatonin. Sleep 2000; 23:663-669.
59. Satomura T, Sakamoto T, Shirakawa S et al. Hypnotic action of melatonin during daytime administration and its comparison with triazolam. Psychiat Clin Neurosci 2001; 55:303-304.
60. Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: Emerging therapeutic targets for sleep disorders. Nat Neurosci 2002; 5:1071-1075.
61. Nave R, Herer P, Haimov I et al. Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: Lack of antagonism by flumazenil. Neurosci Lett 1996; 214:123-126.
62. Zhdanova IV, Wurtman RJ, Regan MM et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86:4727-4730.